Information Provided By: 
Fly News Breaks for April 11, 2019
AGN, EDIT
Apr 11, 2019 | 17:55 EDT
Evercore ISI analyst Ravi Mehrotra initiated Editas Medicine (EDIT) with an Outperform rating and a price targets of $34. The analyst cites the company's "strong clinical positioning of lead program EDIT-101", saying that if its efficacy is demonstrated in LCA-10 and proven durable, it will likely have "significant uptake over Sepofarsen, which requires chronic dosing." Mehrotra adds that Editas Medicine's partnership with Allergan (AGN) "adds reinforcement".
News For EDIT;AGN From the Last 2 Days
There are no results for your query EDIT;AGN
